How FDA Approval of Guardant360 CDx as Companion Diagnostic Could Impact Guardant Health (GH) Investors

Guardant Health announced that the FDA has approved its Guardant360 CDx blood test as a companion diagnostic for Eli Lilly’s Inluriyo, enabling the identification of advanced breast cancer patients ...
Labmate Online

Sixth-generation test transforms emergency heart attack diagnosis

Roche has announced results from the TSIX Study Program, showing that its sixth-generation high-sensitivity Troponin T test ...

FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company’s Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breas…

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...
Labmate Online

FDA clears new companion diagnostic for KMT2A acute leukaemia

OGT, a global provider of genomic diagnostic and research solutions, has announced that the US Food and Drug Administration ...
Inc

A Study Finds More Fentanyl Showing Up in Workplace Drug Tests. Here’s What to Do About It

Data from New Jersey-based drug test provider Quest Diagnostics involved an analysis of over 8 million workplace drug tests carried out during the last year—meaning the results are statistically ...